Puma Biotechnology (PBYI) Total Liabilities (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Total Liabilities came in at $64.3 million in Q1 2026, down 35.12% YoY from $99.1 million in Q1 2025, and down 25.22% on a QoQ basis from $86.0 million in Q4 2025.
Puma Biotechnology (PBYI) Total Liabilities (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 16 years of Total Liabilities data on file, last reported at $64.3 million in Q1 2026.
- Quarterly Total Liabilities fell 35.12% year-over-year to $64.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.3 million (down 35.12% YoY) and the FY2025 annual result came in at $86.0 million, down 29.08% from the prior year.
- Total Liabilities slipped to $64.3 million in Q1 2026, from $86.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $200.5 million in Q4 2022 to a low of $64.3 million in Q1 2026.
- A 5-year average of $143.8 million and a median of $163.2 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities retreated 2.2% — and 2025, when it sank 42.36%.
- Tracing PBYI's Total Liabilities over 5 years: stood at $200.5 million in 2022, then decreased by 11.66% to $177.1 million in 2023, then sank by 31.55% to $121.2 million in 2024, then dropped by 29.08% to $86.0 million in 2025, then fell by 25.22% to $64.3 million in 2026.
- The last three Total Liabilities figures came in at $64.3 million (Q1 2026), $86.0 million (Q4 2025), and $87.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 54.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.19 Mn |
| Mar 31, 2026 | 64.28 Mn |
| Dec 31, 2025 | 85.96 Mn |
| Sep 30, 2025 | 87.59 Mn |
| Jun 30, 2025 | 90.20 Mn |
| Mar 31, 2025 | 99.07 Mn |
| Dec 31, 2024 | 121.21 Mn |
| Sep 30, 2024 | 149.63 Mn |
| Jun 30, 2024 | 156.49 Mn |
| Mar 31, 2024 | 163.17 Mn |
| Dec 31, 2023 | 177.09 Mn |
| Sep 30, 2023 | 164.86 Mn |
| Jun 30, 2023 | 170.10 Mn |
| Mar 31, 2023 | 170.41 Mn |
| Dec 31, 2022 | 200.45 Mn |
| Sep 30, 2022 | 176.62 Mn |
| Jun 30, 2022 | 173.91 Mn |
| Mar 31, 2022 | 193.54 Mn |
| Dec 31, 2021 | 229.03 Mn |
| Sep 30, 2021 | 237.21 Mn |